Infigratinib

  • TRADE NAME: Truseltiq (Helsinn)
  • INDICATIONS: Cholangiocarcinoma (in adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement).
  • CLASS: Fibroblast growth factor receptor inhibitor, Kinase inhibitor
  • HALF-LIFE: 33.5 hours
  • FDA APPROVAL DATE: 05/28/2021
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    antacids, CYP3A Inducers, CYP3A Inhibitors, histamine-2 (H2) receptor antagonists, Itraconazole, Lansoprazole, proton pump inhibitors, Rifampin
  • PREGNANCY: Insufficient data on use in pregnant women. Advise against breastfeeding during treatment and for 1 month after the last dose.

Investigated for treating COVID-19.

Infigratinib can cause retinal pigment epithelial detachment (RPED), which may result in symptoms such as blurred vision. Perform a comprehensive ophthalmic examination including optical coherence tomography prior to initiation of infigratinib, at 1 month, at 3 months, and then every 3 months thereafter during treatment.

Please login to view the rest of this drug profile.

Page last updated 04/07/2026

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top